StreetInsider.com News Articles

Leqembi Iqlik® for initiation treatment launched in the US

Mon, 24 Aug 2026 08:39:00 -0400

STOCKHOLM, Aug. 24, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today announced that lecanemab-irmb subcutaneous injection (US brand name: Leqembi Iqlik®), which was approved by the FDA on July 13, now is available in the US for initiation therapy for early Alzheimer's disease[1]. Leqembi Iqlik is the first-of-its-kind anti-amyloid treatment that offers at-home dosing for initiation and maintenance (approved in the US).

Leqembi Iqlik is administered via an autoinjector, introducing a convenient alternative to intravenous (IV) infusion from the start of treatment. For initiation, the approved regimen is 500

Leqembi Iqlik® for initiation treatment launched in the US

Mon, 24 Aug 2026 08:39:00 -0400

Leqembi Iqlik is administered via an autoinjector, introducing a convenient alternative to intravenous (IV) infusion from the start of treatment. For initiation, the approved regimen is 500

Leqembi Iqlik® for initiation treatment launched in the US

Mon, 24 Aug 2026 08:39:00 -0400

Leqembi Iqlik is administered via an autoinjector, introducing a convenient alternative to intravenous (IV) infusion from the start of treatment. For initiation, the approved regimen is 500

Leqembi Iqlik® for initiation treatment launched in the US

Mon, 24 Aug 2026 08:39:00 -0400

Leqembi Iqlik is administered via an autoinjector, introducing a convenient alternative to intravenous (IV) infusion from the start of treatment. For initiation, the approved regimen is 500

Leqembi Iqlik® for initiation treatment launched in the US

Mon, 24 Aug 2026 08:39:00 -0400

Leqembi Iqlik is administered via an autoinjector, introducing a convenient alternative to intravenous (IV) infusion from the start of treatment. For initiation, the approved regimen is 500

Leqembi Iqlik® for initiation treatment launched in the US

Mon, 24 Aug 2026 08:39:00 -0400

Leqembi Iqlik is administered via an autoinjector, introducing a convenient alternative to intravenous (IV) infusion from the start of treatment. For initiation, the approved regimen is 500

Leqembi Iqlik® for initiation treatment launched in the US

Mon, 24 Aug 2026 08:39:00 -0400

Leqembi Iqlik is administered via an autoinjector, introducing a convenient alternative to intravenous (IV) infusion from the start of treatment. For initiation, the approved regimen is 500

Leqembi Iqlik® for initiation treatment launched in the US

Mon, 24 Aug 2026 08:39:00 -0400

Leqembi Iqlik is administered via an autoinjector, introducing a convenient alternative to intravenous (IV) infusion from the start of treatment. For initiation, the approved regimen is 500

Leqembi Iqlik® for initiation treatment launched in the US

Mon, 24 Aug 2026 08:39:00 -0400

Leqembi Iqlik is administered via an autoinjector, introducing a convenient alternative to intravenous (IV) infusion from the start of treatment. For initiation, the approved regimen is 500

Leqembi Iqlik® for initiation treatment launched in the US

Mon, 24 Aug 2026 08:39:00 -0400

Leqembi Iqlik is administered via an autoinjector, introducing a convenient alternative to intravenous (IV) infusion from the start of treatment. For initiation, the approved regimen is 500

Leqembi Iqlik® for initiation treatment launched in the US

Mon, 24 Aug 2026 08:39:00 -0400

Leqembi Iqlik is administered via an autoinjector, introducing a convenient alternative to intravenous (IV) infusion from the start of treatment. For initiation, the approved regimen is 500

Leqembi Iqlik® for initiation treatment launched in the US

Mon, 24 Aug 2026 08:39:00 -0400

Leqembi Iqlik is administered via an autoinjector, introducing a convenient alternative to intravenous (IV) infusion from the start of treatment. For initiation, the approved regimen is 500

Leqembi Iqlik® for initiation treatment launched in the US

Mon, 24 Aug 2026 08:39:00 -0400

Leqembi Iqlik is administered via an autoinjector, introducing a convenient alternative to intravenous (IV) infusion from the start of treatment. For initiation, the approved regimen is 500

Leqembi Iqlik® for initiation treatment launched in the US

Mon, 24 Aug 2026 08:39:00 -0400

Leqembi Iqlik is administered via an autoinjector, introducing a convenient alternative to intravenous (IV) infusion from the start of treatment. For initiation, the approved regimen is 500

Leqembi Iqlik® for initiation treatment launched in the US

Mon, 24 Aug 2026 08:39:00 -0400

Leqembi Iqlik is administered via an autoinjector, introducing a convenient alternative to intravenous (IV) infusion from the start of treatment. For initiation, the approved regimen is 500

Leqembi Iqlik® for initiation treatment launched in the US

Mon, 24 Aug 2026 08:39:00 -0400

Leqembi Iqlik is administered via an autoinjector, introducing a convenient alternative to intravenous (IV) infusion from the start of treatment. For initiation, the approved regimen is 500

BioArctic and Mesenkia enter oncology research collaboration

Wed, 19 Aug 2026 05:42:00 -0400

STOCKHOLM, August 19, 2026 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) and Mesenkia Therapeutics announced today that the companies have signed a research collaboration agreement to explore a novel antibody-based approach for glioblastoma, one of the most aggressive and treatment-resistant forms of brain cancer, where effective delivery of large molecules to the brain remains a major challenge.

The collaboration combines BioArctic's proprietary BrainTransporter™ technology with an antibody, developed with Mesenkia's KITAIbodies® platform. The antibody targets HVEM^[1], a protein found on the surface of certain glioblastoma tumor cells, including tumor stem cells. By addressing these

BioArctic and Mesenkia enter oncology research collaboration

Wed, 19 Aug 2026 05:42:00 -0400

BioArctic and Mesenkia enter oncology research collaboration

Wed, 19 Aug 2026 05:42:00 -0400

BioArctic and Mesenkia enter oncology research collaboration

Wed, 19 Aug 2026 05:42:00 -0400

BioArctic and Mesenkia enter oncology research collaboration

Wed, 19 Aug 2026 05:42:00 -0400

BioArctic and Mesenkia enter oncology research collaboration

Wed, 19 Aug 2026 05:42:00 -0400

BioArctic and Mesenkia enter oncology research collaboration

Wed, 19 Aug 2026 05:42:00 -0400

BioArctic and Mesenkia enter oncology research collaboration

Wed, 19 Aug 2026 05:42:00 -0400

BioArctic and Mesenkia enter oncology research collaboration

Wed, 19 Aug 2026 05:42:00 -0400